BioMarin Pharmaceutical | BMRN - Current Liabilities

Stock Price
62.92
Daily Change
-1.16 -1.81%
Monthly
10.81%
Yearly
-8.82%
Q1 Forecast
62.09

BioMarin Pharmaceutical reported $798.44M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 356.58M 26.56M Sep/2025
Agios Pharmaceuticals USD 82.21M 7.45M Dec/2025
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
Amgen USD 25.49B 3.7B Dec/2025
Bayer EUR 28.96B 825M Sep/2025
Biogen USD 3.35B 59.4M Dec/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Gilead Sciences USD 11.81B 485M Dec/2025
Incyte USD 1.52B 176.44M Dec/2025
Insmed USD 468.87M 51.66M Dec/2025
Ionis Pharmaceuticals USD 903.46M 6.22M Sep/2025
Moderna USD 1.99B 306M Dec/2025
Neurocrine Biosciences USD 743.4M 105.4M Dec/2025
PTC Therapeutics USD 968.43M 102.18M Dec/2025
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Regeneron Pharmaceuticals USD 4.37B 56.7M Dec/2025
Roche Holding CHF 28B 421M Dec/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sanofi EUR 28.35B 9.32B Dec/2025
Sarepta Therapeutics USD 921.42M 1.48M Sep/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
United Therapeutics USD 546.3M 19.2M Sep/2025
Vertex Pharmaceuticals USD 3.86B 614.1M Dec/2025